AI Trends

Google-backed Isomorphic Labs completes $5 billion Series C funding, setting a record for a single round in AI drug discovery

YicaiUpdated Nov 18 13:54

AI summary

Google-backed AI drug discovery company Isomorphic Labs announced the completion of a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with participation from new investors including a16z, while Alphabet continues to invest on a large scale, setting a new global record for the size of a single funding round in the AI drug discovery field. The company's core technology is the drug design engine IsoDDE, which integrates foundational simulation AI models with proprietary Agent, and it has established R&D collaborations with pharmaceutical companies such as Novartis, Eli Lilly, and Johnson & Johnson, with its internal oncology and immunology programs achieving preclinical results. Hassabis said in January this year that he expected to launch the first clinical trials before the end of 2026, a delay from the previous target of the end of 2025; the company currently has no drugs on the market.

Why read this

AI score 69

The $5 billion Series C sets a new record for a single funding round in AI drug discovery; the original article also notes delays to the clinical trial timeline and validation risks, allowing comparison of capital enthusiasm with implementation progress.

Topics

Tags

Body · AI translation

On November 17 local time, Google-affiliated AI drug discovery company Isomorphic Labs announced the completion of a $5 billion (approximately RMB 35.5 billion) Series C funding round, co-led by Greenoaks and Sequoia Capital, with new investors including a16z participating, and Google parent company Alphabet continuing to invest on a large scale. Existing investors such as Temasek, Thrive Capital, and MGX also participated.

This funding round set a new record for the scale of a single funding round in the global AI drug discovery field, coming only half a year after Isomorphic Labs' previous funding round. In May of this year, the company had just secured $2.1 billion in Series B funding, which at the time also set a record for a single funding round in the global AI drug discovery industry. Together with the $600 million in first external funding completed in March 2025, this company, founded only five years ago, has disclosed cumulative funding of $7.7 billion.

Isomorphic Labs was founded in the United Kingdom by Nobel Prize in Chemistry laureate and former Google DeepMind co-founder Demis Hassabis. The company was spun out of Google DeepMind in 2021, with Hassabis serving as CEO. In August of this year, after Hassabis stepped down as CEO of Google DeepMind, he focused on long-term AGI strategy, AI's social impact, and this AI drug discovery company Isomorphic Labs.

Why are investors willing to pour huge sums into an AI company that has no drugs on the market? For Hassabis, this is the next major scientific breakthrough he is trying to achieve with AI, following AlphaFold's successful prediction of protein structures.

Traditional new drug development is a long and expensive process. Researchers need to search through massive numbers of compounds for potentially effective candidate molecules, then repeatedly experiment to optimize their efficacy, safety, and other characteristics. Even after entering clinical trials, the risk of eventual failure remains high.

Isomorphic Labs hopes to greatly improve the efficiency of this process through AI. Its core technology is the proprietary drug design engine IsoDDE, which integrates a series of foundational simulation AI models covering multiple therapeutic areas and different drug types, capable of exploring chemical space and helping R&D teams design, screen, and optimize molecules with desirable drug-like properties.

In addition to simulation models, the company has also developed proprietary Agents for exploring complex biological systems and performing reasoning. Isomorphic Labs says that combining models with Agents has advanced pipelines of multiple types of candidate drugs. At present, the company's internal oncology and immunology projects as well as collaborative projects have achieved preclinical results.

Isomorphic Labs said it has established R&D partnerships with large pharmaceutical companies such as Novartis, Eli Lilly, and Johnson & Johnson to explore the application of AI in different drug R&D projects.

In a blog post, Hassabis mentioned that when Isomorphic Labs was founded, the team believed that biology could be understood and modeled at the most fundamental molecular level, and that AI could significantly accelerate this process. According to him, this funding round will help the company further develop foundational biology models, increase understanding of disease mechanisms, and advance the first therapeutic programs into clinical trials, providing patients with a new generation of medicines.

However, in contrast to the huge funding, Isomorphic Labs still has a long way to go before launching a drug that can be sold on the market.

In January of this year, Hassabis said at the World Economic Forum in Davos that the company expected to launch its first clinical trials by the end of 2026. This timeline has already been delayed compared with the previously stated target of the end of 2025.

This is also the core problem that the AI drug discovery industry has not yet solved: although AI can accelerate the discovery of drug molecules, whether these molecules can become safe and effective drugs still requires lengthy verification. Drug development must not only prove that it can treat human diseases, but also ensure that it does not produce major side effects.

Some industry practitioners believe that although the AI drug R&D field has huge capital bets, the risk of clinical trial failure remains high, "because huge amounts of money cannot guarantee the launch of market-ready drugs." Improvements in model predictive capability do not mean that the entire clinical development cycle can be shortened proportionally.

Isomorphic Labs is undergoing another form of commercialization test in the AI industry. Over the past few years, the market has been accustomed to evaluating the value of AI companies through model rankings, generation speed, and user scale. But in the pharmaceutical field, model performance is only the starting point; ultimately, clinical trial results are needed to prove the actual value of the technology.

Compared with "spending billions of dollars to make chatbots more interesting for half the timeline," some netizens believe that $5 billion spent on tackling diseases seems more worthy of attention. If AI's first truly killer application is not an app but a drug, that is exactly the plot twist he is looking forward to.

Source

Yicai